
Iterum Therapeutics PLC is a biotechnology business based in the US. Iterum Therapeutics shares (ITRM) are listed on the NASDAQ and all prices are listed in US Dollars. Iterum Therapeutics employs 13 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Iterum Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ITRM – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Our top pick for
Beginners

Our top pick for
Building a portfolio

Our top pick for
Advanced traders

Iterum Therapeutics stock price (NASDAQ: ITRM)
Use our graph to track the performance of ITRM stocks over time.Iterum Therapeutics shares at a glance
Latest market close | $0.21 |
---|---|
52-week range | $0.18 - $1.49 |
50-day moving average | $0.23 |
200-day moving average | $0.39 |
Wall St. target price | $1.00 |
PE ratio | 0.8536 |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $0.25 |
Buy Iterum Therapeutics shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Iterum Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Iterum Therapeutics price performance over time
Historical closes compared with the close of $0.213 from 2022-07-01
1 week (2022-06-29) | -3.66% |
---|---|
1 month (2022-06-06) | -5.79% |
3 months (2022-04-05) | -37.81% |
6 months (2022-01-06) | -48.05% |
1 year (2021-07-06) | -83.36% |
---|---|
2 years (2020-07-06) | -81.95% |
3 years (2019-07-03) | 6.64 |
5 years (2017-07-02) | N/A |
Is Iterum Therapeutics stock undervalued or overvalued?
Valuing Iterum Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Iterum Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Iterum Therapeutics's P/E ratio
Iterum Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, Iterum Therapeutics shares trade at around 1x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Iterum Therapeutics financials
Gross profit TTM | $37,000 |
---|---|
Return on assets TTM | -16.35% |
Return on equity TTM | 9.62% |
Profit margin | 0% |
Book value | $0.27 |
Market capitalisation | $39.1 million |
TTM: trailing 12 months
Iterum Therapeutics share dividends
We're not expecting Iterum Therapeutics to pay a dividend over the next 12 months.
Iterum Therapeutics share price volatility
Over the last 12 months, Iterum Therapeutics's shares have ranged in value from as little as $0.175 up to $1.49. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Iterum Therapeutics's is 1.2017. This would suggest that Iterum Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Iterum Therapeutics overview
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland. .
Iterum Therapeutics in the news
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Frequently asked questions
What percentage of Iterum Therapeutics is owned by insiders or institutions?Currently 0.84% of Iterum Therapeutics shares are held by insiders and 3.459% by institutions. How many people work for Iterum Therapeutics?
Latest data suggests 13 work at Iterum Therapeutics. When does the fiscal year end for Iterum Therapeutics?
Iterum Therapeutics's fiscal year ends in December. Where is Iterum Therapeutics based?
Iterum Therapeutics's address is: Fitzwilliam Court, Dublin, Ireland, 2 What is Iterum Therapeutics's ISIN number?
Iterum Therapeutics's international securities identification number is: IE00BF3W0Q35 What is Iterum Therapeutics's CUSIP number?
Iterum Therapeutics's Committee on Uniform Securities Identification Procedures number is: G6333L101
More guides on Finder
-
How to buy Citrine Global (CTGL) stock when it goes public
Everything we know about the Citrine Global IPO, plus information on how to buy in.
-
How to buy Genelux Corporation (GNLX) stock when it goes public
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
-
How to buy Magic Empire Global (MEGL) stock when it goes public
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
-
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
-
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
-
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
-
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
-
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
-
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
-
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Ask an Expert